Hepatorenal Syndrome Type 1: Diagnosis and Treatment

Area of Science:

• Nephrology
• Hepatology
• Internal Medicine

Background:

• Hepatorenal syndrome (HRS) is a severe complication of advanced cirrhosis, leading to high morbidity and mortality.
• Diagnosis of HRS has historically been challenging due to its exclusion-based nature and lack of objective tests.
• Existing diagnostic criteria aim to differentiate functional acute kidney injury from structural causes in cirrhosis patients.

Purpose of the Study:

• To review the diagnostic challenges and evolving criteria for hepatorenal syndrome (HRS).
• To highlight the role of novel urinary biomarkers in objectively diagnosing HRS.
• To discuss current and future therapeutic strategies for HRS.

Main Methods:

• Review of historical and recent diagnostic criteria for HRS.
• Analysis of studies investigating urinary biomarkers (e.g., neutrophil gelatinase-associated lipocalin) for kidney injury in cirrhosis.
• Examination of therapeutic options, including terlipressin and albumin, and areas for future research.

Main Results:

• Accurate diagnosis of HRS remains difficult, often relying on exclusion.
• Urinary biomarkers show promise for objective phenotyping of acute kidney injury in cirrhosis.
• Terlipressin is a first-line therapy for HRS, with ongoing research into optimal use.

Conclusions:

• Objective diagnostic markers are needed to improve HRS diagnosis and timely treatment.
• Inclusion of biomarkers like NGAL and fractional excretion of sodium may enhance future criteria.
• Further research is required to optimize HRS treatment strategies, including terlipressin dosing and ultrasound guidance.